S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13

Hemostemix Stock Forecast, Price & News

+0.01 (+2.00%)
(As of 06/30/2022 11:26 AM ET)
Today's Range
50-Day Range
52-Week Range
21,300 shs
Average Volume
104,995 shs
Market Capitalization
C$17.40 million
P/E Ratio
Dividend Yield
Price Target

Hemostemix MarketRank™ Forecast

Analyst Rating
Short Interest
Dividend Strength
News Sentiment
Insider Trading
Selling Shares
C$93.21 K Sold Last Quarter
Proj. Earnings Growth

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

0.39 out of 5 stars

30 days | 90 days | 365 days | Advanced Chart

Receive HEM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Hemostemix and its competitors with MarketBeat's FREE daily newsletter.

Hemostemix logo

About Hemostemix (CVE:HEM) Stock

Hemostemix Inc., a biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions. The company develops cell therapy products from the patient's own blood, which is a non-invasive source of therapeutic cells. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of critical limb ischemia in Canada and the United States, as well as for the treatment of heart and peripheral arterial diseases. The company is also developing various types of cell products, such as synergetic cell populations and neural cell precursors. Hemostemix Inc. is headquartered in Calgary, Canada.

HEM Stock News Headlines

Hemostemix, Leucrotta Lone Stocks at 52-Week Highs
Hemostemix Announces Settlement Agreement
Hemostemix Announces $2,750,000 Convertible Debenture
Hemostemix Announces Stock Options Grant
Hemostemix Announces Financing
Hemostemix Confirms OTCQB Listing
Hemostemix Confirms OTCQB Application is Filed
Biden moves to oust Trump military academy board appointees
Hemostemix Announces Five Million Unit Private Placement
See More Headlines

Industry, Sector and Symbol

Year Founded


Pretax Margin


Sales & Book Value

Annual Sales
Cash Flow
C$0.01 per share
Book Value
C($0.08) per share


Free Float
Market Cap
C$17.40 million
Not Optionable

Hemostemix Frequently Asked Questions

How has Hemostemix's stock price performed in 2022?

Hemostemix's stock was trading at C$0.16 on January 1st, 2022. Since then, HEM shares have increased by 59.4% and is now trading at C$0.26.
View the best growth stocks for 2022 here

Who are Hemostemix's key executives?

Hemostemix's management team includes the following people:
  • Mr. Thomas A. Smeenk B.A., BA Hons, Co-Founder, Pres, CEO & Director (Age 60, Pay $277.08k)
  • Ms. Christina Wu CPA, Interim Chief Financial Officer
  • Dr. Fraser C. Henderson Sr., M.D., Chief Medical Officer

What other stocks do shareholders of Hemostemix own?

What is Hemostemix's stock symbol?

Hemostemix trades on the Canadian Venture Exchange (CVE) under the ticker symbol "HEM."

How do I buy shares of Hemostemix?

Shares of HEM and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is Hemostemix's stock price today?

One share of HEM stock can currently be purchased for approximately C$0.26.

How much money does Hemostemix make?

Hemostemix (CVE:HEM) has a market capitalization of C$17.40 million.

How can I contact Hemostemix?

Hemostemix's mailing address is Bay 1, PO Box 10, BLACKFALDS, AB T0M 0J0, Canada. The official website for Hemostemix is www.hemostemix.com. The biotechnology company can be reached via phone at +1-403-3409207.

This page (CVE:HEM) was last updated on 7/4/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.